# GSK plc: insider transactions

SEC CIK 1131399. Roles and transactions as reported on Form 4. Latest Form 4 filed 2025-12-15.

## Roles

| Company | Role | Transactions | First | Latest |
| --- | --- | ---: | --- | --- |
| [Wave Life Sciences, Inc.](/companies/wve.md) | 10% owner | 3 | 2023-12-07 | 2025-12-11 |
| [Bicycle Therapeutics plc](/companies/bcyc.md) | 10% owner | 3 | 2020-07-14 | 2020-07-15 |
| [Progyny, Inc.](/companies/pgny.md) | 10% owner | 3 | 2019-10-29 | 2020-05-20 |
| [Fulcrum Therapeutics, Inc.](/companies/fulc.md) | 10% owner | 2 | 2019-07-22 | 2019-07-22 |
| [Bicycle Therapeutics plc](/companies/bcyc.md) | Director, 10% owner | 5 | 2019-05-28 | 2019-05-28 |
| [Spero Therapeutics, Inc.](/companies/spro.md) | 10% owner | 10 | 2017-11-06 | 2018-07-17 |
| [CRISPR Therapeutics AG](/companies/crsp.md) | 10% owner | 6 | 2016-10-18 | 2016-10-24 |

## Transactions: 32

Every transaction reported, newest first. Codes P and S are open-market purchases and sales. Reported price is as stated on the form.

| Date | Company | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | ---: | ---: | ---: | --- |
| 2025-12-11 | [Wave Life Sciences, Inc.](/companies/wve.md) | Purchase (P) | 1,470,000 | $19.00 | $27.9m | [Form 4](/filings/0001999371-25-020336.md) |
| 2024-09-27 | [Wave Life Sciences, Inc.](/companies/wve.md) | Purchase (P) | 2,791,930 | $8.00 | $22.3m | [Form 4](/filings/0001999371-24-012789.md) |
| 2023-12-07 | [Wave Life Sciences, Inc.](/companies/wve.md) | Purchase (P) | 3,300,000 | $5.00 | $16.5m | [Form 4](/filings/0001999371-24-001192.md) |
| 2020-07-15 | [Bicycle Therapeutics plc](/companies/bcyc.md) | Sale (S) | 78 | $19.25 | $1.5k | [Form 4](/filings/0001387131-20-008376.md) |
| 2020-07-15 | [Bicycle Therapeutics plc](/companies/bcyc.md) | Sale (S) | 3,069 | $19.4016 | $59.5k | [Form 4](/filings/0001387131-20-008376.md) |
| 2020-07-14 | [Bicycle Therapeutics plc](/companies/bcyc.md) | Sale (S) | 1,597 | $19.274 | $30.8k | [Form 4](/filings/0001387131-20-008376.md) |
| 2020-05-20 | [Progyny, Inc.](/companies/pgny.md) | Sale (S) | 4,000,000 | $25.75 | $103.0m | [Form 4](/filings/0001387131-20-005115.md) |
| 2019-10-29 | [Progyny, Inc.](/companies/pgny.md) | Conversion (C), derivative | 9,821,190 | $0.00 | $0 | [Form 4](/filings/0001387131-19-008140.md) |
| 2019-10-29 | [Progyny, Inc.](/companies/pgny.md) | Conversion (C) | 9,821,190 | not reported | not reported | [Form 4](/filings/0001387131-19-008140.md) |
| 2019-07-22 | [Fulcrum Therapeutics, Inc.](/companies/fulc.md) | Conversion (C), derivative | 12,500,000 | $0.00 | $0 | [Form 4](/filings/0001140361-19-013355.md) |
| 2019-07-22 | [Fulcrum Therapeutics, Inc.](/companies/fulc.md) | Conversion (C) | 1,785,714 | not reported | not reported | [Form 4](/filings/0001140361-19-013355.md) |
| 2019-05-28 | [Bicycle Therapeutics plc](/companies/bcyc.md) | Conversion (C), derivative | 445,323 | $0.00 | $0 | [Form 4](/filings/0000903423-19-000235.md) |
| 2019-05-28 | [Bicycle Therapeutics plc](/companies/bcyc.md) | Conversion (C), derivative | 625,049 | $0.00 | $0 | [Form 4](/filings/0000903423-19-000235.md) |
| 2019-05-28 | [Bicycle Therapeutics plc](/companies/bcyc.md) | Purchase (P) | 385,714 | $14.00 | $5.4m | [Form 4](/filings/0000903423-19-000235.md) |
| 2019-05-28 | [Bicycle Therapeutics plc](/companies/bcyc.md) | Conversion (C) | 636,366 | not reported | not reported | [Form 4](/filings/0000903423-19-000235.md) |
| 2019-05-28 | [Bicycle Therapeutics plc](/companies/bcyc.md) | Conversion (C) | 893,195 | not reported | not reported | [Form 4](/filings/0000903423-19-000235.md) |
| 2018-07-17 | [Spero Therapeutics, Inc.](/companies/spro.md) | Purchase (P) | 80,000 | $12.50 | $1.0m | [Form 4](/filings/0000903423-18-000400.md) |
| 2017-11-06 | [Spero Therapeutics, Inc.](/companies/spro.md) | Conversion (C), derivative | 3,683,045 | $0.00 | $0 | [Form 4](/filings/0000903423-17-000632.md) |
| 2017-11-06 | [Spero Therapeutics, Inc.](/companies/spro.md) | Conversion (C), derivative | 1,250,000 | $0.00 | $0 | [Form 4](/filings/0000903423-17-000632.md) |
| 2017-11-06 | [Spero Therapeutics, Inc.](/companies/spro.md) | Conversion (C), derivative | 982,906 | $0.00 | $0 | [Form 4](/filings/0000903423-17-000632.md) |
| 2017-11-06 | [Spero Therapeutics, Inc.](/companies/spro.md) | Conversion (C), derivative | 1,483,784 | $0.00 | $0 | [Form 4](/filings/0000903423-17-000632.md) |
| 2017-11-06 | [Spero Therapeutics, Inc.](/companies/spro.md) | Purchase (P) | 428,571 | $14.00 | $6.0m | [Form 4](/filings/0000903423-17-000632.md) |
| 2017-11-06 | [Spero Therapeutics, Inc.](/companies/spro.md) | Conversion (C) | 606,024 | not reported | not reported | [Form 4](/filings/0000903423-17-000632.md) |
| 2017-11-06 | [Spero Therapeutics, Inc.](/companies/spro.md) | Conversion (C) | 328,992 | not reported | not reported | [Form 4](/filings/0000903423-17-000632.md) |
| 2017-11-06 | [Spero Therapeutics, Inc.](/companies/spro.md) | Conversion (C) | 246,272 | not reported | not reported | [Form 4](/filings/0000903423-17-000632.md) |
| 2017-11-06 | [Spero Therapeutics, Inc.](/companies/spro.md) | Conversion (C) | 244,147 | not reported | not reported | [Form 4](/filings/0000903423-17-000632.md) |
| 2016-10-24 | [CRISPR Therapeutics AG](/companies/crsp.md) | Conversion (C), derivative | 211,567 | $0.00 | $0 | [Form 4](/filings/0000903423-16-001320.md) |
| 2016-10-24 | [CRISPR Therapeutics AG](/companies/crsp.md) | Conversion (C), derivative | 2,942,560 | $0.00 | $0 | [Form 4](/filings/0000903423-16-001320.md) |
| 2016-10-24 | [CRISPR Therapeutics AG](/companies/crsp.md) | Purchase (P) | 66,500 | $14.00 | $931.0k | [Form 4](/filings/0000903423-16-001320.md) |
| 2016-10-24 | [CRISPR Therapeutics AG](/companies/crsp.md) | Conversion (C) | 211,567 | not reported | not reported | [Form 4](/filings/0000903423-16-001320.md) |
| 2016-10-24 | [CRISPR Therapeutics AG](/companies/crsp.md) | Conversion (C) | 2,942,560 | not reported | not reported | [Form 4](/filings/0000903423-16-001320.md) |
| 2016-10-18 | [CRISPR Therapeutics AG](/companies/crsp.md) | Grant or award (A), derivative | 30,000 | $0.00 | $0 | [Form 4](/filings/0000903423-16-001314.md) |

Source: SEC EDGAR, Forms 4. Last ingested by Listed: Nov 1, 2026, 10:34 ET. No prices; not investment advice.